PL2146745T3 - Pięcioswoiste przeciwciało - Google Patents

Pięcioswoiste przeciwciało

Info

Publication number: PL2146745T3
Authority: PL; Poland
Prior art keywords: penta; specific antibody; antibody; specific
Prior art date: 2007-04-17

Application number

PL08745931T

Other languages

English (en)

Inventor

Stephanie Jane Clegg

Eric Dobrzynski

Jonathan H Ellis

Volker Germaschewski

Alexis Paul Godillot

Zdenka Ludmila Jonak

Alan P Lewis

John R White

Original Assignee

Glaxosmithkline Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-04-17

Filing date

2008-04-16

Publication date

2015-11-30

2008-04-16 Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc

2015-11-30 Publication of PL2146745T3 publication Critical patent/PL2146745T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Communicable Diseases (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)

PL08745931T 2007-04-17 2008-04-16 Pięcioswoiste przeciwciało PL2146745T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US91222907P	2007-04-17	2007-04-17
US4413208P	2008-04-11	2008-04-11
PCT/US2008/060424 WO2008130969A2 (en)	2007-04-17	2008-04-16	Novel compounds
EP08745931.9A EP2146745B1 (en)	2007-04-17	2008-04-16	penta-specific antibody

Publications (1)

Publication Number	Publication Date
PL2146745T3 true PL2146745T3 (pl)	2015-11-30

Family

ID=39872910

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL08745931T PL2146745T3 (pl)	2007-04-17	2008-04-16	Pięcioswoiste przeciwciało

Country Status (29)

Country	Link
US (3)	US20080262203A1 (pl)
EP (1)	EP2146745B1 (pl)
JP (1)	JP5441885B2 (pl)
KR (1)	KR101560841B1 (pl)
CN (1)	CN101687035B (pl)
AU (1)	AU2008243049B2 (pl)
BR (1)	BRPI0810250A8 (pl)
CA (1)	CA2684626C (pl)
CL (1)	CL2008001071A1 (pl)
CO (1)	CO6251323A2 (pl)
CR (1)	CR11116A (pl)
CY (1)	CY1116671T1 (pl)
DK (1)	DK2146745T3 (pl)
DO (1)	DOP2009000236A (pl)
EA (1)	EA024621B1 (pl)
ES (1)	ES2547475T3 (pl)
HR (1)	HRP20150937T1 (pl)
HU (1)	HUE027584T2 (pl)
IL (1)	IL201440A (pl)
MA (1)	MA31310B1 (pl)
MX (1)	MX2009011153A (pl)
MY (1)	MY150525A (pl)
NZ (1)	NZ580239A (pl)
PE (1)	PE20090302A1 (pl)
PL (1)	PL2146745T3 (pl)
PT (1)	PT2146745E (pl)
SI (1)	SI2146745T1 (pl)
TW (1)	TWI473815B (pl)
WO (1)	WO2008130969A2 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN104761637B (zh)	2006-03-31	2021-10-15	中外制药株式会社	调控抗体血液动力学的方法
CN101874042B9 (zh)	2007-09-26	2019-01-01	中外制药株式会社	利用cdr的氨基酸取代来改变抗体等电点的方法
EP2275443B1 (en)	2008-04-11	2015-12-02	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US8324352B2 (en)	2009-12-07	2012-12-04	Decimmune Therapeutics, Inc.	Anti-inflammatory antibodies and uses therefor
JP2013518606A (ja) *	2010-02-09	2013-05-23	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	新規使用
TWI654204B (zh)	2010-11-30	2019-03-21	Chugai Seiyaku Kabushiki Kaisha	具有鈣依存性的抗原結合能力之抗體
WO2013125667A1 (ja)	2012-02-24	2013-08-29	中外製薬株式会社	FcγRIIBを介して抗原の消失を促進する抗原結合分子
EP2844290A4 (en) *	2012-05-01	2015-12-16	Glaxosmithkline Llc	NOVEL ANTIBODIES
SG11201500873XA (en)	2012-08-24	2015-04-29	Chugai Pharmaceutical Co Ltd	Fcgriib-specific fc region variant
WO2014030750A1 (ja)	2012-08-24	2014-02-27	中外製薬株式会社	マウスFcγRII特異的Fc抗体
US9409977B2 (en)	2013-03-12	2016-08-09	Decimmune Therapeutics, Inc.	Humanized, anti-N2 antibodies
JO3580B1 (ar)	2013-03-15	2020-07-05	Lilly Co Eli	أجسام مضادة لكيموكين elr+ cxc شامل
US9290570B2 (en)	2013-03-15	2016-03-22	Eli Lilly And Company	Pan-ELR+ CXC Chemokine Antibodies
TWI636062B (zh)	2013-04-02	2018-09-21	中外製藥股份有限公司	Fc region variant
EP2796875B8 (en) *	2013-04-23	2020-11-25	Albert-Ludwigs-Universität Freiburg	Inhibitors of proteins specific for the secretome of a chondrocyte for use in the treatment of breast cancer metastasis
US10047156B2 (en)	2013-05-17	2018-08-14	Centre National De La Recherche Scientifique (Cnrs)	Anti-CXCL1, CXCL7 and CXCL8 antibodies and their applications
NZ730607A (en)	2014-12-19	2022-07-01	Chugai Pharmaceutical Co Ltd	Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
WO2016125495A1 (en)	2015-02-05	2016-08-11	Chugai Seiyaku Kabushiki Kaisha	Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
WO2017110981A1 (en)	2015-12-25	2017-06-29	Chugai Seiyaku Kabushiki Kaisha	Anti-myostatin antibodies and methods of use
BR112019001902A2 (pt)	2016-08-05	2019-07-09	Chugai Seiyaku Kabushiki Kaisha	composição para profilaxia ou tratamento de doenças relacionadas à il-8
SG10201607778XA (en)	2016-09-16	2018-04-27	Chugai Pharmaceutical Co Ltd	Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
US11485781B2 (en)	2017-08-17	2022-11-01	Massachusetts Institute Of Technology	Multiple specificity binders of CXC chemokines
EP3694545A4 (en)	2017-10-11	2021-12-01	Board Of Regents, The University Of Texas System	HUMAN PD-L1 ANTIBODIES AND METHOD OF USING THEM
CA3093729A1 (en)	2018-03-15	2019-09-19	Chugai Seiyaku Kabushiki Kaisha	Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
CA3092695A1 (en)	2018-03-23	2019-09-26	Board Of Regents, The University Of Texas System	Human pd-l2 antibodies and methods of use therefor
US12187799B2 (en)	2018-03-23	2025-01-07	Board Of Regents, The University Of Texas System	Dual specificity antibodies to PD-L1 and PD-L2 and methods of use therefor
WO2019182867A1 (en)	2018-03-23	2019-09-26	Board Of Regents, The University Of Texas System	Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
IL293195A (en) *	2019-12-05	2022-07-01	Seagen Inc	Anti-avb6 antibodies and antibody-drug conjugates
TW202206457A (zh) *	2020-04-24	2022-02-16	美商美國禮來大藥廠	用於治療呼吸疾病之泛elr+ cxc趨化因子抗體
US20220080044A1 (en) *	2020-09-14	2022-03-17	National Yang-Ming University	Method for preventing or treating peripheral arterial occlusive disease
WO2026060205A1 (en)	2024-09-13	2026-03-19	Eli Lilly And Company	PAN-ELR+ CXC CHEMOKINE ANTIBODIES AND IL-23p19 ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE913192A1 (en) *	1990-09-12	1992-02-25	Scripps Research Inst	Active site of interleukin-8: polypeptide analogs and¹antibodies
US6448379B1 (en) *	1993-09-14	2002-09-10	Chiron Corporation	IL8 inhibitors
ATE266726T1 (de) *	1995-06-07	2004-05-15	Ortho Pharma Corp	CDR-TRANSPLANTIERTE ANTIKÖRPER GEGEN ßTISSUE FACTORß UND VERFAHREN ZUR DEREN VERWENDUNG
GB0020685D0 (en) *	2000-08-22	2000-10-11	Novartis Ag	Organic compounds
AR030753A1 (es) *	2000-09-25	2003-09-03	Smithkline Beecham Corp	Uso de moduladores-proteina de il-8, groalfa, grobeta, grogamma, nap-2, y ena-78, para tratar infecciones viricas
TR200300478T2 (tr) *	2000-10-13	2004-10-21	Biogen Inc.	Hümanize antiLT-ß-R antikorları
WO2002088185A2 (en) *	2001-04-26	2002-11-07	Dakocytomation Denmark A/S	Pan-specific monoclonal antibody
US20040022726A1 (en) *	2002-06-03	2004-02-05	Goldenberg David M.	Methods and compositions for intravesical therapy of bladder cancer
AU2003299641C1 (en)	2002-12-16	2016-06-02	Cormorant Pharmaceuticals Ab	Human monoclonal antibodies against interleukin 8 (IL-8)
AU2003303543A1 (en) *	2002-12-26	2004-07-29	Chugai Seiyaku Kabushiki Kaisha	Agonist antibody against heteroreceptor
WO2005094882A1 (en) *	2004-03-03	2005-10-13	Millennium Pharmaceuticals, Inc.	Modified antibodies to prostate-specific membrane antigen and uses thereof
WO2006074399A2 (en) *	2005-01-05	2006-07-13	Biogen Idec Ma Inc.	Multispecific binding molecules comprising connecting peptides
KR20080031001A (ko) *	2005-06-02	2008-04-07	아스트라제네카 아베	Ｃｄ20에 대한 항체 및 그의 용도
KR101246504B1 (ko) *	2005-06-17	2013-03-26	임클론 엘엘씨	항－ＰＤＧＦＲα 항체
GB0519398D0 (en) *	2005-09-23	2005-11-02	Antisoma Plc	Biological materials and uses thereof
WO2007056411A2 (en) *	2005-11-08	2007-05-18	Genentech, Inc.	Method of producing pan-specific antibodies
US8454960B2 (en) *	2008-01-03	2013-06-04	The Scripps Research Institute	Multispecific antibody targeting and multivalency through modular recognition domains

2008
- 2008-04-15 CL CL2008001071A patent/CL2008001071A1/es unknown
- 2008-04-16 JP JP2010504204A patent/JP5441885B2/ja not_active Expired - Fee Related
- 2008-04-16 MX MX2009011153A patent/MX2009011153A/es active IP Right Grant
- 2008-04-16 HR HRP20150937TT patent/HRP20150937T1/hr unknown
- 2008-04-16 EP EP08745931.9A patent/EP2146745B1/en not_active Not-in-force
- 2008-04-16 DK DK08745931.9T patent/DK2146745T3/en active
- 2008-04-16 AU AU2008243049A patent/AU2008243049B2/en not_active Ceased
- 2008-04-16 SI SI200831489T patent/SI2146745T1/sl unknown
- 2008-04-16 BR BRPI0810250A patent/BRPI0810250A8/pt not_active Application Discontinuation
- 2008-04-16 US US12/103,761 patent/US20080262203A1/en not_active Abandoned
- 2008-04-16 KR KR1020097023814A patent/KR101560841B1/ko not_active Expired - Fee Related
- 2008-04-16 ES ES08745931.9T patent/ES2547475T3/es active Active
- 2008-04-16 CA CA2684626A patent/CA2684626C/en not_active Expired - Fee Related
- 2008-04-16 PL PL08745931T patent/PL2146745T3/pl unknown
- 2008-04-16 US US12/596,262 patent/US8496932B2/en not_active Expired - Fee Related
- 2008-04-16 CN CN2008800205593A patent/CN101687035B/zh not_active Expired - Fee Related
- 2008-04-16 PE PE2008000664A patent/PE20090302A1/es not_active Application Discontinuation
- 2008-04-16 HU HUE08745931A patent/HUE027584T2/en unknown
- 2008-04-16 WO PCT/US2008/060424 patent/WO2008130969A2/en not_active Ceased
- 2008-04-16 TW TW97113788A patent/TWI473815B/zh not_active IP Right Cessation
- 2008-04-16 PT PT87459319T patent/PT2146745E/pt unknown
- 2008-04-16 MY MYPI20094336 patent/MY150525A/en unknown
- 2008-04-16 NZ NZ580239A patent/NZ580239A/en not_active IP Right Cessation
- 2008-04-16 EA EA200970954A patent/EA024621B1/ru not_active IP Right Cessation
2009
- 2009-10-08 DO DO2009000236A patent/DOP2009000236A/es unknown
- 2009-10-11 IL IL201440A patent/IL201440A/en not_active IP Right Cessation
- 2009-10-15 MA MA32279A patent/MA31310B1/fr unknown
- 2009-10-19 CO CO09116578A patent/CO6251323A2/es active IP Right Grant
- 2009-11-17 CR CR11116A patent/CR11116A/es unknown
2013
- 2013-06-26 US US13/927,352 patent/US8828384B2/en not_active Expired - Fee Related
2015
- 2015-09-01 CY CY20151100768T patent/CY1116671T1/el unknown

Also Published As

Publication number	Publication date
WO2008130969A3 (en)	2008-12-18
BRPI0810250A8 (pt)	2017-02-21
HK1136970A1 (en)	2010-07-16
JP2010524469A (ja)	2010-07-22
IL201440A (en)	2016-08-31
ES2547475T3 (es)	2015-10-06
EP2146745A4 (en)	2011-11-30
IL201440A0 (en)	2010-06-16
AU2008243049B2 (en)	2011-04-21
CA2684626C (en)	2014-11-04
EA024621B1 (ru)	2016-10-31
EP2146745A2 (en)	2010-01-27
EP2146745B1 (en)	2015-06-17
CR11116A (es)	2010-03-22
MA31310B1 (fr)	2010-04-01
HRP20150937T1 (hr)	2015-10-09
HUE027584T2 (en)	2016-11-28
CN101687035A (zh)	2010-03-31
JP5441885B2 (ja)	2014-03-12
DOP2009000236A (es)	2009-11-15
CO6251323A2 (es)	2011-02-21
US20140010807A1 (en)	2014-01-09
CN101687035B (zh)	2013-06-12
TWI473815B (zh)	2015-02-21
US8496932B2 (en)	2013-07-30
CA2684626A1 (en)	2008-10-30
US20110229475A1 (en)	2011-09-22
WO2008130969A2 (en)	2008-10-30
KR20100020946A (ko)	2010-02-23
CL2008001071A1 (es)	2009-05-22
MX2009011153A (es)	2009-10-30
MY150525A (en)	2014-01-30
KR101560841B1 (ko)	2015-11-11
US8828384B2 (en)	2014-09-09
US20080262203A1 (en)	2008-10-23
PT2146745E (pt)	2015-10-14
BRPI0810250A2 (pt)	2014-10-14
SI2146745T1 (sl)	2015-10-30
CY1116671T1 (el)	2017-03-15
TW200906855A (en)	2009-02-16
AU2008243049A1 (en)	2008-10-30
PE20090302A1 (es)	2009-04-03
EA200970954A1 (ru)	2010-08-30
DK2146745T3 (en)	2015-09-14
NZ580239A (en)	2012-07-27

Publication	Publication Date	Title
PT2146745E (pt)	2015-10-14	Anticorpo pentaespecífico
EP2138576A4 (en)	2011-02-23	ANTI-CLAUDIN-4 ANTIBODY
GB0708002D0 (en)	2007-06-06	Antibodies
SI2200700T1 (sl)	2016-04-29	Nova protitelesa
ZA201102119B (en)	2011-12-28	Improved antibody libraies
ZA201002422B (en)	2014-06-25	Modified antibody constant region
EP2077859A4 (en)	2010-11-24	ANTIBODY FORMULATION
IL206103A0 (en)	2010-11-30	Antibody formulation
GB0821100D0 (en)	2008-12-24	Antibodies
IL202648A0 (en)	2011-08-01	Antibody formulations
ZA200909107B (en)	2012-12-27	Antibody formulations
ZA201002275B (en)	2011-06-29	Il-23 antibodies
IL205073A0 (en)	2010-11-30	Anti-bst2 antibody
EP2173163A4 (en)	2010-12-08	ANTIBODY FORMULATIONS
GB0718737D0 (en)	2007-11-07	Antibodies
PT2011869E (pt)	2014-07-09	Novo anticorpo anti-cd98
IL207581A0 (en)	2010-12-30	Anti-tyrp1 antibodies
GB0702888D0 (en)	2007-03-28	Novel Antibodies
GB0615662D0 (en)	2006-09-13	Antibody
ZA201007976B (en)	2012-02-29	Anti-pirb antibodies
GB0818356D0 (en)	2008-11-12	Antibodies
GB0911770D0 (en)	2009-08-19	Antibody
EP2167635A4 (en)	2010-06-30	ANTIBODY FORMULATIONS
GB0724185D0 (en)	2008-01-23	Antibodies
GB0817621D0 (en)	2008-11-05	Antibody